Nile Therapeutics names drug-development veteran as CEO

Darlene Horton.

Nile Therapeutics Inc. named Dr. Darlene Horton, a founder of Itero Biopharmaceuticals, as president and CEO. Horton, who initially was appointed Nile's chief medical officer in June, replacesJoshua Kazam, who served as part-time president and CEO of San Mateo-based Nile (OTC: NLTX) and whose Two River Group Holdings invested in Nile. The company is developing cenderitide, a treatment for acutely decompensated heart failure patients after they leave the hospital.